Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re interested in reporting on any of this month’s stories, contact media@fredhutch.org ...

A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine ...

Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others.

AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer. Patients from racially and ethnically ...

In cancer research, one person's junk is increasingly becoming another person's treasure. Scientists have now uncovered new evidence showing how recently evolved "junk DNA" genetic elements can become ...

According to the Cleveland Clinic, a quarter of cancer deaths can be attributed to one source: cachexia. Cachexia is a syndrome that accompanies underlying chronic illness and causes unwanted muscle ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...